文献速递呼吸危重症与机械通气间质性肺疾病呼吸道感染

COVID-19 患者的肺移植:综述

Lung Transplantation for Patients With COVID-19.
PubMed 文献 · Chest · 2021-08-19

综述讨论 COVID-19 相关急性呼吸窘迫综合征(CARDS)及感染后肺纤维化患者的肺移植问题。全球有限病例已成功实施肺移植,但重症 CARDS 患者面临心理社会评估困难、危重症去适应及病毒再激活等挑战;感染后肺纤维化患者则因自然转归知识有限而决策困难。肺移植对部分 COVID-19 严重肺损伤患者可为挽救生命的治疗选择。

要点

  • 重症 CARDS 患者肺移植面临心理社会评估受限、危重症去适应和病毒再激活风险。
  • 感染后肺纤维化患者肺移植决策需权衡自然恢复可能性与移植风险获益。
  • 肺移植对部分 COVID-19 严重肺损伤患者可为挽救生命的治疗选择。

核心结论

  • 肺移植对部分 COVID-19 严重肺损伤患者可为挽救生命的治疗选择。
  • 全球有限病例中肺移植已成功用于 CARDS 和感染后肺纤维化。

研究设计与样本

  • 综述,由多个有经验中心的肺移植提供者讨论 CARDS 或感染后肺纤维化的肺移植方法。

主要发现

  • 重症 CARDS 患者肺移植面临心理社会评估和移植前教育无法进行、危重症去适应及病毒再激活感染顾虑等主要障碍。
  • 感染后肺纤维化患者因 COVID-19 感染后恢复自然史知识有限而决策困难。
  • 肺移植医生需对可能稳定或逐渐改善的感染后肺纤维化患者与已知进展性纤维化间质性肺疾病(fILD)患者权衡不同的移植风险获益。

临床怎么用

  • 对重症 CARDS 无法脱离机械通气或感染后肺纤维化导致严重残疾需长期补氧者,治疗团队常询问肺移植可能性。
  • 肺移植决策需考虑 COVID-19 急性肺损伤后恢复的可能性与程度。

局限性

  • 全球肺移植用于 CARDS 和感染后肺纤维化的患者数量有限。
  • 对 COVID-19 感染后恢复自然史的知识有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic has caused acute lung injury in millions of individuals worldwide. Some patients develop COVID-related acute respiratory distress syndrome (CARDS) and cannot be liberated from mechanical ventilation. Others may develop post-COVID fibrosis, resulting in substantial disability and need for long-term supplemental oxygen. In both of these situations, treatment teams often inquire about the possibility of lung transplantation. In fact, lung transplantation has been successfully employed for both CARDS and post-COVID fibrosis in a limited number of patients worldwide. Lung transplantation after COVID infection presents a number of unique challenges that transplant programs must consider. In those with severe CARDS, the inability to conduct proper psychosocial evaluation and pretransplantation education, marked deconditioning from critical illness, and infectious concerns regarding viral reactivation are major hurdles. In those with post-COVID fibrosis, our limited knowledge about the natural history of recovery after COVID-19 infection is problematic. Increased knowledge of the likelihood and degree of recovery after COVID-19 acute lung injury is essential for appropriate decision-making with regard to transplantation. Transplant physicians must weigh the risks and benefits of lung transplantation differently in a post-COVID fibrosis patient who is likely to remain stable or gradually improve in comparison with a patient with a known progressive fibrosing interstitial lung disease (fILD). Clearly lung transplantation can be a life-saving therapeutic option for some patients with severe lung injury from COVID-19 infection. In this review, we discuss how lung transplant providers from a number of experienced centers approach lung transplantation for CARDS or post-COVID fibrosis.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. King CS, Mannem H, Kukreja J, et al. Lung Transplantation for Patients With COVID-19. Chest. 2021. PMID: 34418410. doi:10.1016/j.chest.2021.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。